Innovative Targeting Solutions Generates the World’s First Peptide-Grafted Antibody Agonist to the G Protein-Coupled Receptor GLP1-R
December 9, 2013
Burnaby, B.C., Canada. December 9th, 2013. – Innovative Targeting Solutions Inc. (ITS) a pioneer in novel protein engineering technologies, today announced the successful application of the company’s HuTARG technology for the generation of peptide-grafted antibody agonists against the GLP1 receptor. The breakthrough was possible because the HuTARG technology’s ability to generate large de novo libraries of peptide-grafted antibodies directly in an engineered reporter cell-line. Utilizing this new strategy ITS was able to generate 100’s of millions of variants and directly screen them for functional activity. The identification and isolation of these rare peptide-grafted antibodies that activate the GLP-1 receptor signalling demonstrates the power of working in a mammalian system and the unique advantages that the HuTARG technology offers by enabling the convergence of functional assays directly with diversity generation.
The data will be presented at IBC’s 2013 Antibody Engineering & Antibody Therapeutics conference and a copy of the poster can be downloaded from http://itsas01.azurewebsites.net/pigott-et-al-antibody-engineering-2013/
About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately‐held company that has developed the HuTARG technology a next generation protein engineering platform for the generation and maturation of fully human antibody therapeutics. The HuTARG technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination.